Application Nr Approved Date Route Status External Links
NDA204410 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Opsumit Is An Endothelin Receptor Antagonist (Era) Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah, Who Group I) To Reduce The Risks Of Disease Progression And Hospitalization For Pah ( 1.1 ). 1.1 Pulmonary Arterial Hypertension Opsumit Is An Endothelin Receptor Antagonist (Era) Indicated For The Treatment Of Pulmonary Arterial Hypertension (Pah, Who Group I) To Reduce The Risks Of Disease Progression And Hospitalization For Pah. Effectiveness Was Established In A Long-Term Study In Pah Patients With Predominantly Who Functional Class Ii-Iii Symptoms Treated For An Average Of 2 Years. Patients Had Idiopathic And Heritable Pah (57%), Pah Caused By Connective Tissue Disorders (31%), And Pah Caused By Congenital Heart Disease With Repaired Shunts (8%) [See Clinical Studies (14.1) ] .

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Macitentan MACITENTAN ZINC43202140

Comments